Andrea Charles | 11/04/2012
                                    
                    
                                                With budget cuts hitting hard in the R&D field, it is imperative to validate the worth of predictive methods internally as they continue to facilitate the reduction in late stage drug attrition. But the challenges remain: how do we cost-effectively develop and implement these in-vitro methods as accurately and as early in the drug discovery process as possible?Jorrit J. Hornberg, PhD Head of Section In Vitro Studies, Exploratory Toxicology  at Lundbeck, speaks to Andrea Charles fro...
                    To continue reading this story Click Here
                                    
                            Upcoming Events
Pharmaceutical Launch Excellence Summit
                            2 - 3 December, 2025
                            
 
                            UK
                            
                             Register Now |
                            View Agenda |
                            Learn More
                        
Pharma Contract Manufacturing
                            23 - 25 March 2026
                            
 
                            Mercure Hotel MOA Berlin, Germany
                            
                             Register Now |
                            View Agenda |
                            Learn More